Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-03-18 00:00:00 ET · period of report 2022-03-16 · accession 0001708138-22-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-18 | 2022-03-17 | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $682.50 | -286 | 29.0K | -1.0% | -$195.2K |
| DM | 2022-03-18 | 2022-03-16+ | REGN | Landry Robert E | EVP Fin CFO | S - Sale+OE | $678.95 | -383 | 28.9K | -1% | -$260.0K |
| D | 2022-03-18 | 2022-03-17 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +365 | 29.2K | +1% | +$139.4K |
| D | 2022-03-18 | 2022-03-17 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -365 | 19.2K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-17 | F | D | 286 | $682.50 | 28,956 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-16 | S | D | 300 | $677.00 | 28,960 | D | — | — | |
| 3 | Common | Common Stock | 2022-03-17 | S | D | 83 | $686.00 | 28,877 | D | — | — | |
| 4 | Common | Common Stock | 2022-03-17 | M | A | 365 | $381.92 | 29,242 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-03-17 | M | D | 365 | $0.00 | 19,200 | D | $381.92 · — to 2026-12-16 | 365 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |